Ariela R Orkaby1, Kelly Cho2, Jean Cormack2, David R Gagnon2, Jane A Driver2. 1. From the VA Boston Geriatric Research, Education, and Clinical Center (GRECC) and Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) (A.R.O., K.C., J.C., D.R.G., J.A.D.); Division of Aging (A.R.O., K.C., J.A.D.), Brigham & Women's Hospital, Harvard Medical School; and Boston University School of Public Health Department of Biostatistics (D.R.G.), MA. aorkaby@partners.org. 2. From the VA Boston Geriatric Research, Education, and Clinical Center (GRECC) and Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) (A.R.O., K.C., J.C., D.R.G., J.A.D.); Division of Aging (A.R.O., K.C., J.A.D.), Brigham & Women's Hospital, Harvard Medical School; and Boston University School of Public Health Department of Biostatistics (D.R.G.), MA.
Abstract
OBJECTIVE: To determine whether metformin is associated with a lower incidence of dementia than sulfonylureas. METHODS: This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia. Follow-up began after 2 years of therapy. To account for confounding by indication, we developed a propensity score (PS) and used inverse probability of treatment weighting (IPTW) methods. Cox proportional hazards models estimated the hazard ratio (HR) of incident dementia. RESULTS: We identified 17,200 new users of metformin and 11,440 new users of sulfonylureas. Mean age was 73.5 years and mean HbA1c was 6.8%. Over an average follow-up of 5 years, 4,906 cases of dementia were diagnosed. Due to effect modification by age, all analyses were conducted using a piecewise model for age. Crude hazard ratio [HR] for any dementia in metformin vs sulfonylurea users was 0.67 (95% confidence interval [CI] 0.61-0.73) and 0.78 (95% CI 0.72-0.83) for those <75 years of age and ≥75 years of age, respectively. After PS IPTW adjustment, results remained significant in veterans <75 years of age (HR 0.89; 95% CI 0.79-0.99), but not for those ≥75 years of age (HR 0.96; 95% CI 0.87-1.05). A lower risk of dementia was also seen in the subset of younger veterans who had HbA1C values ≥7% (HR 0.76; 95% CI 0.63-0.91), had good renal function (HR 0.86; 95% CI 0.76-0.97), and were white (HR 0.87; 95% CI 0.77-0.99). CONCLUSIONS: After accounting for confounding by indication, metformin was associated with a lower risk of subsequent dementia than sulfonylurea use in veterans <75 years of age. Further work is needed to identify which patients may benefit from metformin for the prevention of dementia.
OBJECTIVE: To determine whether metformin is associated with a lower incidence of dementia than sulfonylureas. METHODS: This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia. Follow-up began after 2 years of therapy. To account for confounding by indication, we developed a propensity score (PS) and used inverse probability of treatment weighting (IPTW) methods. Cox proportional hazards models estimated the hazard ratio (HR) of incident dementia. RESULTS: We identified 17,200 new users of metformin and 11,440 new users of sulfonylureas. Mean age was 73.5 years and mean HbA1c was 6.8%. Over an average follow-up of 5 years, 4,906 cases of dementia were diagnosed. Due to effect modification by age, all analyses were conducted using a piecewise model for age. Crude hazard ratio [HR] for any dementia in metformin vs sulfonylurea users was 0.67 (95% confidence interval [CI] 0.61-0.73) and 0.78 (95% CI 0.72-0.83) for those <75 years of age and ≥75 years of age, respectively. After PS IPTW adjustment, results remained significant in veterans <75 years of age (HR 0.89; 95% CI 0.79-0.99), but not for those ≥75 years of age (HR 0.96; 95% CI 0.87-1.05). A lower risk of dementia was also seen in the subset of younger veterans who had HbA1C values ≥7% (HR 0.76; 95% CI 0.63-0.91), had good renal function (HR 0.86; 95% CI 0.76-0.97), and were white (HR 0.87; 95% CI 0.77-0.99). CONCLUSIONS: After accounting for confounding by indication, metformin was associated with a lower risk of subsequent dementia than sulfonylurea use in veterans <75 years of age. Further work is needed to identify which patients may benefit from metformin for the prevention of dementia.
Authors: Nisa M Maruthur; Eva Tseng; Susan Hutfless; Lisa M Wilson; Catalina Suarez-Cuervo; Zackary Berger; Yue Chu; Emmanuel Iyoha; Jodi B Segal; Shari Bolen Journal: Ann Intern Med Date: 2016-04-19 Impact factor: 25.391
Authors: Wilma Helena Oliveira; Ana Karolina Nunes; Maria Eduarda Rocha França; Laise Aline Santos; Deniele Bezerra Lós; Sura Wanessa Rocha; Karla Patrícia Barbosa; Gabriel Barros Rodrigues; Christina Alves Peixoto Journal: Brain Res Date: 2016-05-10 Impact factor: 3.252
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Saion Chatterjee; Sanne A E Peters; Mark Woodward; Silvia Mejia Arango; G David Batty; Nigel Beckett; Alexa Beiser; Amy R Borenstein; Paul K Crane; Mary Haan; Linda B Hassing; Kathleen M Hayden; Yutaka Kiyohara; Eric B Larson; Chung-Yi Li; Toshiharu Ninomiya; Tomoyuki Ohara; Ruth Peters; Tom C Russ; Sudha Seshadri; Bjørn H Strand; Rod Walker; Weili Xu; Rachel R Huxley Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Jeffrey F Scherrer; John E Morley; Joanne Salas; James S Floyd; Susan A Farr; Sascha Dublin Journal: Ann Fam Med Date: 2019-07 Impact factor: 5.166
Authors: Sonja K Soo; Paige D Rudich; Annika Traa; Namasthée Harris-Gauthier; Hazel J Shields; Jeremy M Van Raamsdonk Journal: Mech Ageing Dev Date: 2020-06-28 Impact factor: 5.432
Authors: Jeffrey F Scherrer; Joanne Salas; James S Floyd; Susan A Farr; John E Morley; Sascha Dublin Journal: Mayo Clin Proc Date: 2019-08 Impact factor: 7.616
Authors: Tajudeen Olabisi Obafemi; Oluwaseun R Olasehinde; Oyindamola A Olaoye; Kikelomo F Jaiyesimi; Funmilayo D Adewumi; Olusola B Adewale; Blessing A Afolabi Journal: J Diabetes Metab Disord Date: 2020-05-16